Pink SheetElevar Therapeutics, a US subsidiary of South Korea’s HLB LifeScience, and China’s Jiangsu Hengrui Pharmaceuticals on 21 March received a complete response letter from the US Food and Drug Administrat
ScripThroughout 2024 and against persistent financial headwinds, novice and returning sole Chinese company sponsors of clinical trials initiated a total of seven new global Phase III programs that included
ScripInnovent Biologics, Inc. , Transcenta Holding Ltd. and Shanghai Henlius Biotech Co. Ltd. are leading Chinese drug makers’ latest efforts to extend the high-stakes undertaking of global pivotal Pha
ScripTORL BioTherapeutics LLC is aiming for its latest fundraise to take it past the regulatory finish line with TORL-1-23, which it calls a first-in-class antibody-drug conjugate (ADC) targeting Claudin